Ensign Peak Advisors, Inc Bellus Health Inc. Transaction History

Ensign Peak Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $1.94 Million - $2.59 Million	216,216 Added 112.2%	408,916 $4.32 Million
Q2 2022 Aug 12, 2022	SELL	$6.46 - $10.02 $4.9 Million - $7.61 Million	-759,171 Reduced 79.76%	192,700 $1.78 Million
Q4 2021 Feb 11, 2022	BUY	$5.26 - $8.3 $2.95 Million - $4.65 Million	560,798 Added 143.4%	951,871 $7.66 Million
Q3 2021 Nov 12, 2021	BUY	$2.7 - $6.64 $1.06 Million - $2.6 Million	391,073 New	391,073 $2.4 Million
Q3 2020 Nov 12, 2020	SELL	$2.14 - $12.02 $86,862 - $487,891	-40,590 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$8.88 - $11.15 $181,445 - $227,827	20,433 Added 101.37%	40,590 $418,000
Q1 2020 May 11, 2020	SELL	$5.77 - $10.85 $116,300 - $218,692	-20,156 Reduced 50.0%	20,157 $201,000
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $232,202 - $306,378	40,313 New	40,313 $306,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.